{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators
Vertex Pharmaceuticals has recently revised its market evaluation, with its stock priced at $402.90. Over the past year, the company has seen an 11.51% decline, contrasting with the S&P 500's 17.82% return. Technical indicators present a mixed outlook, while Vertex has achieved a 54.38% return over five years.
Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Vertex Pharmaceuticals has a mildly bearish technical trend, with mixed indicators showing underperformance compared to the S&P 500, suggesting limited upward momentum.
Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Vertex Pharmaceuticals is in a mildly bearish trend, indicated by a bearish MACD and moving averages, despite a bullish monthly RSI, and has underperformed the S&P 500 over the past year with a return of -11.08% compared to 17.82%.
Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Vertex Pharmaceuticals has a mildly bearish trend, indicated by bearish signals from the weekly MACD and KST, despite a bullish RSI, and has underperformed the S&P 500 with a year-to-date return of 0.15% compared to 14.18% for the index.
Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?
As of September 11, 2025, Vertex Pharmaceuticals is in a mildly bearish trend, indicated by a bearish MACD and Bollinger Bands, with a year-to-date return of -3.87%, significantly underperforming the S&P 500's 12.22%.
Is Vertex Pharmaceuticals, Inc. overvalued or undervalued?
As of August 4, 2025, Vertex Pharmaceuticals has shifted from a risky to an attractive valuation grade, but it appears overvalued compared to peers, with a year-to-date return of -3.87% and a one-year return of -18.36%, significantly underperforming the S&P 500.
Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?
As of June 27, 2025, Vertex Pharmaceuticals, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and Bollinger Bands, despite a bullish RSI suggesting some momentum divergence.
Is Vertex Pharmaceuticals, Inc. overvalued or undervalued?
As of August 1, 2024, Vertex Pharmaceuticals is considered overvalued with a negative P/E ratio of -202.76 and unfavorable valuation metrics compared to peers, indicating significant financial losses and inefficiencies in generating profit.
Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?
As of June 20, 2025, the market trend has shifted to bearish with moderate strength, driven by bearish signals from the weekly MACD and KST, despite bullish RSI readings on longer time frames.
Who are in the management team of Vertex Pharmaceuticals, Inc.?
As of March 2022, the management team of Vertex Pharmaceuticals, Inc. is led by Dr. Jeffrey Leiden (Executive Chairman) and Dr. Reshma Kewalramani (President and CEO), along with several independent directors including Mr. Bruce Sachs, Dr. Sangeeta Bhatia, Mr. Lloyd Carney, Dr. Alan Garber, and Mr. Terrence Kearney.
What does Vertex Pharmaceuticals, Inc. do?
Vertex Pharmaceuticals, Inc. focuses on discovering and commercializing medicines for serious diseases, primarily cystic fibrosis. As of March 2025, it reported net sales of $2.746 billion and a net profit of $646 million, with a market cap of approximately $113.5 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
